BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 26482887)

  • 1. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
    Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
    Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance.
    van As NJ; de Souza NM; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC
    Eur Urol; 2009 Dec; 56(6):981-7. PubMed ID: 19095345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
    Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
    Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy.
    Vasarainen H; Lahdensuo K; Savolainen R; Ruutu M; Taari K; Rannikko A
    Scand J Urol; 2013 Dec; 47(6):456-61. PubMed ID: 23327661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series.
    Fossati N; Karnes RJ; Boorjian SA; Moschini M; Morlacco A; Bossi A; Seisen T; Cozzarini C; Fiorino C; Noris Chiorda B; Gandaglia G; Dell'Oglio P; Joniau S; Tosco L; Shariat S; Goldner G; Hinkelbein W; Bartkowiak D; Haustermans K; Tombal B; Montorsi F; Van Poppel H; Wiegel T; Briganti A
    Eur Urol; 2017 Jun; 71(6):886-893. PubMed ID: 27484843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prebiopsy multiparametric MRI-based risk score for predicting prostate cancer in biopsy-naive men with prostate-specific antigen between 4-10 ng/mL.
    Dwivedi DK; Kumar R; Dwivedi AK; Bora GS; Thulkar S; Sharma S; Gupta SD; Jagannathan NR
    J Magn Reson Imaging; 2018 May; 47(5):1227-1236. PubMed ID: 28872226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer-Data from the International Multicenter Prospective PRIAS Study.
    Luiting HB; Remmers S; Boevé ER; Valdagni R; Chiu PK; Semjonow A; Berge V; Tully KH; Rannikko AS; Staerman F; Roobol MJ
    Eur Urol Oncol; 2022 Dec; 5(6):651-658. PubMed ID: 35437217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer.
    Jayadevan R; Felker ER; Kwan L; Barsa DE; Zhang H; Sisk AE; Delfin M; Marks LS
    JAMA Netw Open; 2019 Sep; 2(9):e1911019. PubMed ID: 31509206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
    Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
    Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance.
    Morgan VA; Riches SF; Thomas K; Vanas N; Parker C; Giles S; Desouza NM
    Br J Radiol; 2011 Jan; 84(997):31-7. PubMed ID: 21172965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study.
    Stavrinides V; Giganti F; Trock B; Punwani S; Allen C; Kirkham A; Freeman A; Haider A; Ball R; McCartan N; Whitaker H; Orczyk C; Emberton M; Moore CM
    Eur Urol; 2020 Sep; 78(3):443-451. PubMed ID: 32360049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
    Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
    Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of prostate cancer lesions with high and with low Gleason score by diffusion-weighted MRI.
    Barbieri S; Brönnimann M; Boxler S; Vermathen P; Thoeny HC
    Eur Radiol; 2017 Apr; 27(4):1547-1555. PubMed ID: 27300199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Stratification of Prostate Cancer Using the Combination of Histogram Analysis of Apparent Diffusion Coefficient Across Tumor Diffusion Volume and Clinical Information: A Pilot Study.
    Zhang Z; Xu H; Xue Y; Li J; Ye Q
    J Magn Reson Imaging; 2019 Feb; 49(2):556-564. PubMed ID: 30173421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.
    Hashimoto T; Rahul K; Takeda T; Benfante N; Mulhall JP; Hricak H; Eastham JA; Vargas HA
    Urol Oncol; 2016 Dec; 34(12):530.e9-530.e14. PubMed ID: 27665357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of apparent diffusion coefficient and MR volumetry as independent associative factors for extra-prostatic extension (EPE) in prostatic carcinoma.
    Lim C; Flood TA; Hakim SW; Shabana WM; Quon JS; El-Khodary M; Thornhill RE; El Hallani S; Schieda N
    J Magn Reson Imaging; 2016 Mar; 43(3):726-36. PubMed ID: 26303719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medium-term outcomes of active surveillance for localised prostate cancer.
    Selvadurai ED; Singhera M; Thomas K; Mohammed K; Woode-Amissah R; Horwich A; Huddart RA; Dearnaley DP; Parker CC
    Eur Urol; 2013 Dec; 64(6):981-7. PubMed ID: 23473579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Study of Systematic Biopsy Versus Magnetic Resonance Imaging and Targeted and Systematic Biopsy in Men on Active Surveillance (ASIST): 2-year Postbiopsy Follow-up.
    Klotz L; Pond G; Loblaw A; Sugar L; Moussa M; Berman D; Van der Kwast T; Vesprini D; Milot L; Kebabdjian M; Fleshner N; Ghai S; Chin J; Haider M
    Eur Urol; 2020 Mar; 77(3):311-317. PubMed ID: 31708295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.